ZCCHC9 Inhibitors
ZCCHC9 inhibitors encompass a range of compounds that target various biochemical pathways to attenuate the functional activity of ZCCHC9. Compounds that inhibit protein kinases play a significant role in modulating the activity of ZCCHC9 by altering its phosphorylation status, which is a key regulatory mechanism for its function. Certain kinase inhibitors specifically target the phosphorylation pathway that ZCCHC9 may depend on, while others, like those inhibiting the PI3K/Akt pathway, could suppress the signaling that is potentially crucial for ZCCHC9's role in the cell. The inhibition of mTOR by specific compounds also indirectly diminishes the translation efficiency or stability of ZCCHC9, thereby reducing its activity. Moreover, agents that bind to immunophilins to inhibit phosphatase activity can influence the nuclear factors that may regulate genes interacting with or controlling ZCCHC9's function, further contributing to the decrease in its activity.
In addition to the aforementioned inhibitors, compounds that target the MEK/ERK pathway, p38 MAP kinase, and JNK pathways exert an indirect inhibitory effect on ZCCHC9 by disrupting signaling cascades that ZCCHC9 may be involved in. These compounds can lead to changes in the activity of transcription factors and the expression of genes that interact with ZCCHC9, impacting its functionality. Furthermore, antagonists of calmodulin and compounds that hinder vesicle trafficking disrupt calcium signaling and intracellular transport, respectively, both of which could play a role in ZCCHC9-mediated processes.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
This alkaloid acts as a potent inhibitor of protein kinases, impacting various signaling pathways. By inhibiting kinase activity, it indirectly reduces the functional activity of ZCCHC9, which may rely on phosphorylation events for its activity or interaction with phosphorylated partners. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A specific inhibitor of PI3K, thereby impacting the PI3K/AKT/mTOR pathway. ZCCHC9, which might be regulated by mTOR due to its involvement in mRNA processing, would indirectly experience decreased functional activity due to this upstream inhibition. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Known to form a complex with FKBP12 and bind to mTOR, inhibiting its kinase activity. This results in reduced activity of downstream proteins, potentially including ZCCHC9, due to its possible role in processes regulated by mTOR. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
It selectively inhibits MEK, which is part of the MAPK/ERK pathway. This pathway is involved in the regulation of various cellular processes, which could impact ZCCHC9 function if it is regulated by ERK signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
A selective inhibitor of p38 MAPK, affecting the cellular response to stress and inflammatory cytokines. ZCCHC9 could be influenced by perturbations in p38 MAPK signaling if it participates in stress response pathways. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
An inhibitor of MEK, which is upstream of ERK in the MAPK pathway. By inhibiting MEK, ERK activation is reduced, potentially affecting the function of ZCCHC9 if it is involved in pathways or processes downstream of ERK. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
A potent inhibitor of PI3K, leading to suppression of the PI3K/AKT signaling pathway. As PI3K is involved in numerous cellular functions, ZCCHC9 activity could be indirectly reduced if it is acted upon by proteins within this pathway. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $62.00 $90.00 $299.00 $475.00 $1015.00 $2099.00 | 69 | |
Binds to cyclophilins and inhibits calcineurin, consequently inhibiting NF-AT translocation to the nucleus. If ZCCHC9 is regulated by NF-AT or related signaling, its function would be indirectly inhibited. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of JNK, which is a part of the MAPK signaling pathways. The inhibition of JNK could lead to an indirect decrease in ZCCHC9 activity if it is regulated by stress or apoptosis pathways involving JNK. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
This proteasome inhibitor could lead to the accumulation of regulatory proteins that are normally degraded, potentially affecting the function of ZCCHC9 if it interacts with such proteins. | ||||||